[Remote] Director of Oncology Marketing, Pathology at Natera

San Carlos, California, United States

Natera Logo
Not SpecifiedCompensation
Expert & Leadership (9+ years)Experience Level
Full TimeJob Type
UnknownVisa
Biotechnology, Diagnostics, Pharmaceuticals, Genomics, OncologyIndustries

Requirements

Candidates should possess a Bachelor's degree in life sciences and have 8-10 years of experience in diagnostics, biotech, or pharma marketing, with a focus on oncology, genomics, or advanced diagnostics. Experience with comprehensive genomic profiling (CGP) is strongly preferred, and willingness to travel up to 25% is required. Deep knowledge of the genomic profiling landscape and its clinical applications is essential, along with strong communication, collaboration, strategic thinking, and operational skills.

Responsibilities

The Director of Marketing for Oncology (Pathology) will lead strategic and tactical marketing efforts for Natera’s tissue-based solutions, crafting compelling campaigns and value propositions for pathologists and molecular pathologists across various channels. This role involves partnering with sales, medical, product, and UX teams, identifying and building relationships with key opinion leaders, and tracking, analyzing, and optimizing marketing performance. The position also requires serving as a cross-functional thought leader for Altera and Signatera in portfolio-level initiatives and presenting to executive leadership.

Skills

Oncology Marketing
Pathology Marketing
Genomics Marketing
Biotech Marketing
Pharma Marketing
Comprehensive Genomic Profiling (CGP)
Signatera
Altera™
Marketing Strategy
Campaign Development
Value Proposition
Digital Marketing
Sales Materials
Key Opinion Leader (KOL) Relationship Management
Marketing Performance Analysis
Cross-functional Leadership
Life Sciences

Natera

Genetic testing and diagnostics solutions provider

About Natera

Natera focuses on genetic testing and diagnostics, providing advanced solutions for cancer patients, transplant patients, and individuals assessing hereditary health risks. Their main technology is cell-free DNA (cfDNA) testing, which analyzes DNA fragments in the blood to detect minimal traces of cancer and assess organ health. Natera stands out by offering specialized tests like the Signatera ctDNA test and Panorama NIPT, along with genetic counseling services. The company's goal is to improve patient care and health outcomes through accurate genetic testing.

Austin, TexasHeadquarters
2004Year Founded
$149.9MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
1,001-5,000Employees

Benefits

Flexible medical plans
Investment options
Time off
Workplace perks

Risks

Hindenburg report accuses Natera of deceptive sales practices, risking legal challenges.
New Prospera Heart features may face slow adoption by healthcare providers.
Fetal RhD NIPT demand may drop post-RhIg shortage, affecting future sales.

Differentiation

Natera's Signatera test offers personalized ctDNA analysis for cancer patients.
Prospera Heart test uses unique Donor Quantity Score for transplant rejection detection.
Panorama NIPT test is a leader in non-invasive prenatal testing with 2 million tests.

Upsides

Increased adoption of liquid biopsy techniques boosts demand for Natera's cfDNA tests.
AI integration enhances accuracy and speed of Natera's cfDNA analysis.
Growing personalized medicine trend aligns with Natera's customized genetic tests.

Land your dream remote job 3x faster with AI